 |
|
Experimental flu vaccine appears promising in early tests
April 11, 2007An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.
"All currently licensed influenza vaccines in the United States are produced in embryonated hen's eggs. There are several well-recognized disadvantages to the use of eggs as the substrate [the base on which an organism lives or grows] for influenza vaccine. Eggs require specialized manufacturing facilities and could be difficult to scale up rapidly in response to an emerging need such as a pandemic," the authors write. They add that development of alternative substrates for influenza vaccine production has been identified as a high-priority. One potential alternative is use of the influenza virus hemagglutinin (HA; an antibody that causes red blood cells to clump together) using recombinant (genetic recombination) DNA techniques.
John J. Treanor, M.D., of the University of Rochester, N.Y., and colleagues evaluated an experimental influenza vaccine consisting of recombinant HA expressed in insect cells by a recombinant baculovirus (rHA0). The clinical trial was conducted at three U.S. academic medical centers during the 2004-2005 influenza season and included 460 healthy adults. Participants were randomly assigned to receive a single injection of saline placebo (n = 154); 75 µg of an rHA0 vaccine containing 15 µg of hemagglutinin from influenza A/New Caledonia/20/99(H1N1) and influenza B/Jiangsu/10/03 virus and 45 µg of hemagglutinin from influenza A/Wyoming/3/03 (H3N2) virus (n = 153); or 135 µg of rHA0 containing 45 µg of hemagglutinin each from all 3 components (n = 153). Serum samples were taken before and 30 days following immunization.
The researchers found: "We have shown that the rHA0 vaccine is well tolerated in healthy adults and immunogenic at both doses evaluated, and we obtained preliminary evidence of protection against influenza infection and disease. The safety data generated in this study are consistent with the safety profile observed in previous studies of rHA0 vaccine. These vaccines have been well tolerated at all doses administered and are associated with low rates of local reactions."
"The use of recombinant DNA techniques to express proteins in cell culture has been a successful approach for generation of highly effective vaccines for the prevention of hepatitis B virus and human papillomavirus. Among the available expression technologies, recombinant baculovirus is especially well suited for production of influenza vaccine because the rapidity with which genes can be cloned and inserted into this vector facilitates updating the vaccine at regular intervals. In addition, the extraordinarily high yields of protein possible in this system provide the opportunity to use much higher and potentially more effective doses of vaccine. Expression of the HA protein in insect cells using recombinant baculovirus also avoids the need to work with potentially pathogenic live influenza viruses and the attendant biocontainment issues that would be a particular concern for generation of pandemic vaccines. The preliminary demonstration of protective efficacy in adults provides further support for the development of this promising approach for prevention of seasonal and pandemic influenza," the authors conclude.
JAMA and Archives Journals
The researchers found: "We have shown that the rHA0 vaccine is well tolerated in healthy adults and immunogenic at both doses evaluated, and we obtained preliminary evidence of protection against influenza infection and disease. The safety data generated in this study are consistent with the safety profile observed in previous studies of rHA0 vaccine. These vaccines have been well tolerated at all doses administered and are associated with low rates of local reactions."
"The use of recombinant DNA techniques to express proteins in cell culture has been a successful approach for generation of highly effective vaccines for the prevention of hepatitis B virus and human papillomavirus. Among the available expression technologies, recombinant baculovirus is especially well suited for production of influenza vaccine because the rapidity with which genes can be cloned and inserted into this vector facilitates updating the vaccine at regular intervals. In addition, the extraordinarily high yields of protein possible in this system provide the opportunity to use much higher and potentially more effective doses of vaccine. Expression of the HA protein in insect cells using recombinant baculovirus also avoids the need to work with potentially pathogenic live influenza viruses and the attendant biocontainment issues that would be a particular concern for generation of pandemic vaccines. The preliminary demonstration of protective efficacy in adults provides further support for the development of this promising approach for prevention of seasonal and pandemic influenza," the authors conclude.
JAMA and Archives Journals
Influenza Current Events and Influenza News RSSResearchers recreate SARS virus, open door for potential defenses against future strains
Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.
Study of ancient and modern plagues finds common features
In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta.
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Common cold virus came from birds
A virus that causes cold-like symptoms in humans originated in birds and may have crossed the species barrier around 200 years ago, according to an article published in the December issue of the Journal of General Virology. Scientists hope their findings will help us understand how potentially deadly viruses emerge in humans.
The health burden of raising a grandchild
Precautionary health measures such as mammograms and cholesterol tests that identify the risk of heart disease are critical for the well-being of women over 50. Add the responsibility of providing sustained care for a grandchild, and these preventive examinations become even more important.
Protein 'tubules' free avian flu virus from immune recognition
A protein found in the virulent avian influenza virus strain called H5N1 forms tiny tubules in which it "hides" the pieces of double-stranded RNA formed during viral infection, which otherwise would prompt an antiviral immune response from infected cells, said Baylor College of Medicine researchers in an online report in the journal Nature.
Flu vaccination rates lag for at-risk adolescents
Influenza vaccination rates for adolescents who suffer from asthma and other illnesses are still far too low, according to a recent study.
New intranasal influenza vaccine triggers robust immunity with significantly less antigen
A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation.
More Influenza Current Events and Influenza News Articles
 | The Great Influenza: The Epic Story of the Deadliest Plague In History by John M. Barry In the winter of 1918, at the height of WWI, history’s most lethal influenza virus erupted in an army camp in Kansas, moved east with American troops, then exploded, killing as many as 100 million people worldwide. It killed more people in twenty-four weeks than AIDS has killed in twenty-four years, more in a year than the Black Death killed in a century. But this was not the Middle Ages, and... |
 | Flu: A Social History of Influenza by Tom Quinn This fascinating book explores the havoc caused by the world's most deadly virus - and the destruction left behind in its... |
 | Flu: The Story Of The Great Influenza Pandemic by Gina Kolata When we think of plagues, we think of AIDS, Ebola, anthrax spores, and, of course, the Black Death. But in 1918 the Great Flu Epidemic killed an estimated 40 million people virtually overnight. If such a plague returned today, taking a comparable percentage of the U.S. population with it, 1.5 million Americans would die.In Flu, Gina Kolata, an acclaimed reporter for The New York Times, unravels... |
 | Avian Influenza Avian Influenza provides the first comprehensive guide covering the full spectrum of this complex and increasingly high-profile disease, its history and its treatment and control. All aspects of avian influenza are dealt with in depth, systematically covering biology, virology, diagnostics, ecology, epidemiology, clinical medicine, and the control. The book fuses coverage of the latest... |
| The Great Influenza (The Epic Story of the Deadliest Plague in History) | |
| FLU, Story of the Great Influenza Pandemic of 1918 & Search for the Virus That Caused it by Gina Kolata | |
 | Combating the Threat of Pandemic Influenza: Drug Discovery Approaches Drug discovery for influenza antivirals Priorities for combating pandemic influenza include rapid detection and identification, the quick administration of available drugs to treat the infection, the development of new antivirals, and the development of vaccines. Since lead-time may be required to produce an effective vaccine, antivirals would serve as a key first line of defense in... |
 | Avian Influenza Virus (Methods in Molecular Biology) With the growing global fear of a major pandemic, avian influenza virus research has increased greatly in importance during this young century. In Avian Influenza Virus, an expert team of researchers and diagnosticians examine the fundamental yet essential virological methods for AI virus research and diagnostics as well as some of the newest molecular procedures currently used for basic and... |
 | America's Forgotten Pandemic: The Influenza of 1918 by Alfred W. Crosby Between August 1918 and March 1919 the Spanish influenza spread worldwide, claiming over 25 million lives, more people than those perished in the fighting of the First World War. It proved fatal to at least a half-million Americans. Yet, the Spanish flu pandemic is largely forgotten today. In this vivid narrative, Alfred W. Crosby recounts the course of the pandemic during the panic-stricken... |
| Influenza and Other Viruses (Perspectives on Disease and Illness) by Judy Monroe |
| © 2008 BrightSurf.com |